Pancreatic Cancer Research

ResearcherInstituto de Salud Carlos IIIActive in the last 2 years

Mariano Barbacid

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1480-2624; OpenAlex author ID A5056668478. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  2. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Last author DOI 10.1073/pnas.2523039122↗
  3. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  4. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Co-author DOI 10.1053/j.gastro.2014.08.002↗
  5. Genetically engineered mouse models of pancreatic adenocarcinoma. First author DOI 10.1016/j.molonc.2013.02.002↗
  6. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗
  7. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ccr.2012.08.001↗
  8. What we have learned about pancreatic cancer from mouse models. Co-author DOI 10.1053/j.gastro.2012.03.002↗
  9. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Last author DOI 10.1016/j.ccr.2011.05.011↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carmen E. Guerra · 9 shared papers, 2011–2026 · strength 0.67
  2. Bruno Sáinz · 3 shared papers, 2014–2026 · strength 0.43
  3. Juan Carlos López-Gil · 2 shared papers, 2025–2026 · strength 0.39
  4. Patricia Sancho · 2 shared papers, 2014–2026 · strength 0.24
  5. Beatriz Parejo-Alonso · 1 shared paper, 2026 · strength 0.21
  6. Antonio Agostini · 1 shared paper, 2026 · strength 0.21
  7. Sonia Alcalá · 1 shared paper, 2026 · strength 0.21
  8. Lívia Archibugi · 1 shared paper, 2026 · strength 0.21
  9. Pilar Acedo · 1 shared paper, 2026 · strength 0.21
  10. Ana Galván-del-Rey · 1 shared paper, 2026 · strength 0.21
  11. Claudio Luchini · 1 shared paper, 2026 · strength 0.21
  12. Gabriele Capurso · 1 shared paper, 2026 · strength 0.21
  13. Carmine Carbone · 1 shared paper, 2026 · strength 0.21
  14. Stephen P. Pereira · 1 shared paper, 2026 · strength 0.21
  15. Julie Earl · 1 shared paper, 2026 · strength 0.21
  16. Francisco Sanchez Bueno · 1 shared paper, 2025 · strength 0.18
  17. Sara Barrambana · 1 shared paper, 2025 · strength 0.18
  18. Vasiliki Liaki · 1 shared paper, 2025 · strength 0.18
  19. Nelson Dusetti · 1 shared paper, 2025 · strength 0.18
  20. Carlos Plaza · 2 shared papers, 2013–2014 · strength 0.06
  21. Rafael Álvarez · 2 shared papers, 2013–2014 · strength 0.06
  22. Jesús Rodríguez-Pascual · 2 shared papers, 2013–2014 · strength 0.06
  23. Yolanda Quijano · 2 shared papers, 2013–2014 · strength 0.06
  24. Emilio Vicente · 2 shared papers, 2013–2014 · strength 0.06
  25. Manuel M. Hidalgo · 2 shared papers, 2013–2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.